Connect Sign InGenomic-Driven Precision Oncology With Next Generation Sequencing Testing
Comprehensive genomic testing with next-generation sequencing (NGS) can inform clinicians with valuable insights into available genomic-based targeted treatments and immunotherapies for cancer patients. However, implementing an effective and well-organized clinical precision oncology program can be challenging due to ever-growing and ever-changing molecular testing and treatment standards. This presentation will describe key components of precision cancer medicine: NGS testing, Molecular-Tumor-Board, and a review of 2021 FDA-approved new oncologic drugs. The presentation will conclude with a case study in precision oncology with a lung cancer patient with brain metastasis.
Jong Taek Kim, MD, MS is a medical director of molecular oncology at ARUP Laboratories and an assistant professor of clinical pathology at the University of Utah Department of Pathology. Dr. Kim specializes in molecular oncology and biomedical informatics. He received his master’s degree in biomedical informatics at the University of Florida College of Medicine before completing his medical degree at the University of South Alabama College of Medicine. He then completed an orthopedic surgery residency at the Medical University of South Carolina and an anatomic and clinical pathology residency at the University of Florida College of Medicine. Following that, Dr. Kim finished a fellowship in molecular genetic pathology at Cedars-Sinai Medical Center. He is board certified in anatomic and clinical pathology and molecular genetics pathology. Dr. Kim is a member of the United States and Canadian Academy of Pathology, the American Society for Clinical Pathology, and the College of American Pathologists. His research interests include oncologic genomics by next generation sequencing, bioinformatics, biomedical informatics, and applications of AI methodology in healthcare.
